Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

Summary

This study is a randomized, open-label, multicenter Phase III clinical trial involving patients with relapsed/refractory multiple myeloma. The estimated total sample size is 260 cases, who will be randomly assigned in a 1:1 ratio to the test group and the control group. The primary objective of the study is to demonstrate the efficacy of TQB2934 for injection compared to the investigator-selected regimen in subjects with relapsed or refractory multiple myeloma (RRMM) by evaluating progression-free survival (PFS).

Timeline

Start

2026-06

Primary completion

2028-12

Completion

2030-12

Drugs

Indications